Image Source: AsiaOne
OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition BoothPoster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3GlobeNewswireMay 17, 2022TAIPEI, Taiwan, May 17, 2022 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) meeting from June 3–7, 2022 in Chicago, IL (USA). These studies will be presented by the lead investigators of OBI Pharma’s first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).
Source: AsiaOne